Limits...
Multiparametric-MRI in diagnosis of prostate cancer.

Ghai S, Haider MA - Indian J Urol (2015 Jul-Sep)

Bottom Line: Multiparametric-magnetic resonance imaging (mp-MRI) has shown promising results in diagnosis, localization, risk stratification and staging of clinically significant prostate cancer.It has also opened up opportunities for focal treatment of prostate cancer.This review focuses on the present status of mp-MRI in prostate cancer and its evolving role in the management of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Joint Department of Medical Imaging, University Health Network, University of Toronto, Ontario, Canada.

ABSTRACT
Multiparametric-magnetic resonance imaging (mp-MRI) has shown promising results in diagnosis, localization, risk stratification and staging of clinically significant prostate cancer. It has also opened up opportunities for focal treatment of prostate cancer. Combinations of T2-weighted imaging, diffusion imaging, perfusion (dynamic contrast-enhanced imaging) and spectroscopic imaging have been used in mp-MRI assessment of prostate cancer, but T2 morphologic assessment and functional assessment by diffusion imaging remains the mainstay for prostate cancer diagnosis on mp-MRI. Because assessment on mp-MRI can be subjective, use of the newly developed standardized reporting Prostate Imaging and Reporting Archiving Data System scoring system and education of specialist radiologists are essential for accurate interpretation. This review focuses on the present status of mp-MRI in prostate cancer and its evolving role in the management of prostate cancer.

No MeSH data available.


Related in: MedlinePlus

Extracapsular extension of tumor. A 64-year-old male with biopsy-confirmed Gleason 7 (3 + 4) prostate carcinoma. Axial T2-weighted image obtained with the endorectal coil shows the low signal tumor in the left peripheral zone with minimal extension along the left neurovascular bundle (arrow)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4495493&req=5

Figure 3: Extracapsular extension of tumor. A 64-year-old male with biopsy-confirmed Gleason 7 (3 + 4) prostate carcinoma. Axial T2-weighted image obtained with the endorectal coil shows the low signal tumor in the left peripheral zone with minimal extension along the left neurovascular bundle (arrow)

Mentions: The degree of intensity decrease on T2WI in the peripheral zone has been correlated with Gleason grade of tumor, with higher Gleason score components showing lower signal intensities, thereby playing a role in risk stratification of tumor.[20] The high spatial resolution of T2WI makes the sequence also the mainstay for local staging of disease.[21] Low signal intensity extension to seminal vesicles, obliteration of the recto–prostatic angle and extension to neurovascular bundles are signs of extracapsular extension (ECE) of tumor on T2WI [Figure 3]. Lawrence et al. recently reported that addition of DWI and DCE imaging to T2WI improved the accuracy of pre-operative detection of ECE.[11]


Multiparametric-MRI in diagnosis of prostate cancer.

Ghai S, Haider MA - Indian J Urol (2015 Jul-Sep)

Extracapsular extension of tumor. A 64-year-old male with biopsy-confirmed Gleason 7 (3 + 4) prostate carcinoma. Axial T2-weighted image obtained with the endorectal coil shows the low signal tumor in the left peripheral zone with minimal extension along the left neurovascular bundle (arrow)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4495493&req=5

Figure 3: Extracapsular extension of tumor. A 64-year-old male with biopsy-confirmed Gleason 7 (3 + 4) prostate carcinoma. Axial T2-weighted image obtained with the endorectal coil shows the low signal tumor in the left peripheral zone with minimal extension along the left neurovascular bundle (arrow)
Mentions: The degree of intensity decrease on T2WI in the peripheral zone has been correlated with Gleason grade of tumor, with higher Gleason score components showing lower signal intensities, thereby playing a role in risk stratification of tumor.[20] The high spatial resolution of T2WI makes the sequence also the mainstay for local staging of disease.[21] Low signal intensity extension to seminal vesicles, obliteration of the recto–prostatic angle and extension to neurovascular bundles are signs of extracapsular extension (ECE) of tumor on T2WI [Figure 3]. Lawrence et al. recently reported that addition of DWI and DCE imaging to T2WI improved the accuracy of pre-operative detection of ECE.[11]

Bottom Line: Multiparametric-magnetic resonance imaging (mp-MRI) has shown promising results in diagnosis, localization, risk stratification and staging of clinically significant prostate cancer.It has also opened up opportunities for focal treatment of prostate cancer.This review focuses on the present status of mp-MRI in prostate cancer and its evolving role in the management of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Joint Department of Medical Imaging, University Health Network, University of Toronto, Ontario, Canada.

ABSTRACT
Multiparametric-magnetic resonance imaging (mp-MRI) has shown promising results in diagnosis, localization, risk stratification and staging of clinically significant prostate cancer. It has also opened up opportunities for focal treatment of prostate cancer. Combinations of T2-weighted imaging, diffusion imaging, perfusion (dynamic contrast-enhanced imaging) and spectroscopic imaging have been used in mp-MRI assessment of prostate cancer, but T2 morphologic assessment and functional assessment by diffusion imaging remains the mainstay for prostate cancer diagnosis on mp-MRI. Because assessment on mp-MRI can be subjective, use of the newly developed standardized reporting Prostate Imaging and Reporting Archiving Data System scoring system and education of specialist radiologists are essential for accurate interpretation. This review focuses on the present status of mp-MRI in prostate cancer and its evolving role in the management of prostate cancer.

No MeSH data available.


Related in: MedlinePlus